(Incorporated in Switzerland)

We were founded in Switzerland by Dr. Haley Abivardi and Dr. Goly Abivardi—internationally renowned dentists and serial entrepreneurs—with a vision to improve overall health globally by defining and establishing a new category in oral health. Our mission is to create a world where cavity treatment is pain-free, regenerative and accessible to all.

We believe, drawing on our industry experience, market understanding and extensive clinical evidence, that we have created a first-in-category healthcare platform: the first clinically validated treatment for early-stage cavities that helps preserve the natural tooth structure and enables the restoration of enamel crystal density throughout the lesion, in a similar way to how nature built the tooth.

Our proprietary peptide-enabled technology platform, Curodont®, delivers an early therapeutic solution for tooth decay, the world’s most prevalent non-communicable disease, addressing a massive global healthcare need that has historically lacked effective early-intervention medical treatment options.

Our Curodont® platform includes our flagship Curodont® products—Curodont® Repair Fluoride Plus, which is currently sold in the United States and generates the vast majority of our revenues, and Curodont® Repair, which is currently sold in our other markets. Our flagship Curodont® products are based on proprietary, peptide-containing formulations that complement the patient’s natural biology to help it stop the progression of early-stage cavities, preserve natural tooth structure and repair damaged enamel in early-stage cavities, establishing a new drill-free restorative category that we believe aligns clinical and economic incentives for patients, dental practitioners and payors. We have accumulated a robust body of scientific evidence over the last 25 years that demonstrates the clinical performance, tolerability and observed outcomes of Curodont®’s underlying technology.

Following our U.S. commercial launch in January 2024, we have achieved rapid clinical adoption, and estimate that our products have treated over 3.5 million teeth as of June 30, 2026, with our flagship Curodont® products having been sold to over 20,000 of the approximately 110,000 general dental practices in the United States.

Our U.S. product, Curodont Repair Fluoride Plus, is sold in the U.S. as an OTC drug only through Henry Schein. 

Curodont Repair, a fluoride-free version, is sold as a medical device in the UK and some countries in Europe.

Note:  Net loss and revenue are in U.S.  dollars for the 12 months that ended on June 30, 2026.

(Note: vVardis Holding filed  its F-1 on Oct. 9, 2026, for its IPO, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure. Some IPO pros say that vVardis Holding’s IPO could raise about $200 million.)